AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$IDYA

Hata Yujiro S sold $985K of IDYA

Hata Yujiro S (President and CEO) sold 26,338 shares of IDEAYA Biosciences, Inc. (IDYA) at an average of $37.41 ($37.39–$38.26, $0.99M total) across 2 trades on 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hata Yujiro S
Published Oct 8, 2026, 11:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 11:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IDYA
Bearish
medium confidence
Mentioned
$IDYA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IDYABearishLow
01

Why it matters

The transaction reduces insider ownership and may be interpreted as a lack of confidence, prompting short‑term price pressure.

02

Market read

A fresh insider sale of nearly $1M by the CEO, reported via a Form 4 filing, provides new data for traders.

03

What to watch

Potential upcoming clinical data releases or financing needs that prompted the sale.

Relevance 4/10Novelty 4/10Timing: post‑market today

Background

Form 4 filing discloses a recent open‑market sale by IDEAYA Biosciences' CEO.

Company-level read

Ticker impact

$IDYABearishMedium confidence
Context

CEO Hata Yujiro S sold 26,338 shares for $985K via a 10b5-1 plan, reducing his stake to 690,695 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

The sale is sizable for a micro‑cap and executed through a pre‑arranged plan, which often triggers short‑term sell‑off.

Market effects

Sector

Minimal impact on the broader biotech sector; insider sales are company‑specific.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The sale could be routine under a 10b5‑1 plan and not reflect negative sentiment.

Key entities

  • Company
    IDEAYA Biosciences, Inc.

    Biotech firm listed on Nasdaq (IDYA).

  • Person
    Hata Yujiro S

    President, CEO, and Director of IDEAYA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IDYA insider trading history →

Related articles

$IDYAMed

IDEAYA Biosciences Q3 loss widens to $125.7M

IDEAYA Biosciences reported a Q3 2026 net loss of $125.7M, up from $112.5M in Q2, with collaboration revenue rising to $10.2M. Cash reserves fell to $1.15B. The company submitted darovasertib for FDA approval and plans Phase 3 trials, maintaining its cash runway guidance into 2030.

grafa.com
$IDYAHighAI 8/10

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

IDEAYA Biosciences, Inc. (IDYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update • Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanom

SEC EDGAR 8-K
$IDYAHighAI 9/10

IDEAYA Reports Promising IDE849 Results In Small Cell Lung Cancer

IDEAYA Biosciences reported Phase 1 results for IDE849, showing antitumor activity in relapsed small cell lung cancer. Median overall survival was 17.4 months in second-line SCLC and 14.7 months across second-line and later-line patients. The confirmed response rate was 60.8% in second-line SCLC. IDEAYA plans Phase 3 trials. The stock closed at $36.12, up 1.83%, and is down 0.03% in premarket trading.

rttnews.com